Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 21 of 26 · 1223 articles
Diet-based induction options matter for children because EEN can be hard to tolerate. This study finds CDED (with partial enteral nutrition) performs similarly to EEN for inducing remission and mucosal healing in...
Cure8 could only read part of this source from law360.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Access, cost, and policy.
Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...
This trial targets fibrotic narrowings (strictures) in Crohn’s disease — a common complication without approved drug treatments — so positive results could change care options and reduce the need for surgery.
This large real-world study suggests GLP-1 receptor agonists used in adults with Crohn’s disease and obesity were associated with lower healthcare use and lower subsequent TNF inhibitor use at 1 and 5 years, findings...
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
Many people with IBD avoid NSAIDs because of flare concerns. This large study suggests prescription NSAIDs did not meaningfully increase hospitalization risk overall, but patients with Crohn disease showed a higher risk....
This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
The atlas maps which genes and cell types are different in Crohn's disease, offering clues about why inflammation persists and pointing to specific immune pathways (like JAK/STAT) that are already drug targets. The...
Pregnancy planning affects disease and pregnancy outcomes in Crohn’s. Staying in remission and maintaining needed IBD medications during pregnancy reduces risks to both mother and baby, while stopping certain drugs...
People with Crohn's disease often develop intestinal fibrosis and strictures that current drugs don't reverse; a growing drug pipeline aiming at anti‑fibrotic therapies could change future treatment options.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Infliximab. The original article is from gastroendonews.com.
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...
A new national approval means guselkumab (TREMFYA) may soon be an available treatment option for people with Crohn’s disease or ulcerative colitis in Egypt, potentially expanding choices for moderate-to-severe disease....
This study suggests that regional differences in how often and how early advanced drugs are used didn’t change 10-year rates of surgery, hospitalization, or progression to complicated Crohn’s disease in this cohort.
This trial shows darvadstrocel did not outperform placebo for complex perianal Crohn’s fistulas, so it does not support changing care now. High healing rates after surgical curettage and closure suggest the surgical step...
The FDA’s acceptance of Takeda’s sBLA is a regulatory step toward possibly approving IV vedolizumab for children with moderate‑to‑severe UC or Crohn’s. If approved, this would expand an existing adult IBD treatment to...
Long-term (five-year) data suggest guselkumab may provide sustained clinical and endoscopic benefit for people with moderate-to-severe Crohn’s disease, which is important for disease control and reducing need for...
Cure8 found this source from caledonianrecord.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Vedolizumab. Open the original article for the full details.
This could expand an approved, gut-targeted biologic (vedolizumab/ENTYVIO) to children as young as 2 with UC or Crohn’s disease, addressing a pediatric treatment gap if the FDA approves the sBLA. Families and clinicians...
Fibrostenotic Crohn’s disease (intestinal strictures from scar tissue) has few non-surgical treatment options. An investigational drug aimed at fibrosis could eventually offer a medical alternative to surgery if research...
Long-term data help patients and clinicians understand whether a biologic maintains benefit and safety over years. Sustained clinical remission and endoscopic healing are important outcomes linked to better long-term...
This study suggests surgery can help heal severe, noncontiguous (metastatic) skin manifestations of Crohn’s disease when medical therapy alone isn’t enough. It highlights that realistic healing may take many months and...
Routine care and sensible lifestyle choices can reduce flares and complications in Crohn's disease. Missing specialist care, stopping meds, smoking, poor diet, or skipping appointments are common, avoidable risks.
Many people with Crohn’s try cannabis or CBD to ease symptoms. This article explains current evidence is limited: some symptom relief is possible, but there’s no clear proof it reduces gut inflammation and it may risk...
Cure8 found this source from scholarworks.indianapolis.iu.edu, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ustekinumab. Open the original article for the...
GLP-1 drugs are being studied as possible treatments for gut conditions beyond weight loss—researchers are exploring whether they can reduce gut inflammation or improve related liver disease. Patients with IBD, IBS, or...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
This article reports an investigational stem cell therapy (StemSmart MSCs) showing safety and clinical responses in a small group of patients with fistulising Crohn’s disease — a serious complication that’s often hard to...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ustekinumab. Open the original article for the full details.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
Some people with moderate-to-severe Crohn’s who don’t fully respond to one advanced therapy may hear about adding a second drug. This article explains when clinicians might consider that approach, the potential benefits...
This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.
Early “top-down” infliximab plus an immunomodulator was linked to much lower 5-year risk of abdominal surgery, disease progression, and hospitalization versus a step-up approach. This could influence treatment planning...
New clinical results for TREMFYA in perianal fistulizing Crohn's disease and positive data for another J&J IBD drug could signal future treatment options or regulatory milestones that matter to people with Crohn's and...
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.
This affects people with IBD because it describes late-stage testing decisions for a combination biologic therapy that targets ulcerative colitis and Crohn’s disease. If pursued, the approach could change future...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from msn.com.
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. Open the original article for...
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new...
This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...
Based on the title and source metadata, this appears to be a conference abstract related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
